Archives for the month of: December, 2011

The Interpublic Group of Companies is one of the four biggest global advertising holding companies in America, with a full-year revenue of $6.5 million and over 41,000 employees. With lineage that goes back to the 1870s, this institution is one of the United States’ earliest advertising agencies. It wasn’t until a century later that the company went public. Since then, the Interpublic Group of Companies has continued to be a leader in its respective industry.

During the 2009 economic recession, a lot of major companies felt threatened. Despite longevity and stability, their stocks fell, costing them millions of dollars of possible returns. While their competitors were on the brink of bankruptcy, the Interpublic Group of Companies remained strong. It was business as usual for them, as well as nine other companies that stayed strong during the recession. Their services, which include consumer advertising, interactive marketing, media planning, and public relations, became an asset for other institutions that struggled with rapidly declining economic conditions. The company was not invincible to the effects of the market plunge, but damage to their business was so minimal that they were able to rise above others.

The company’s story of success, however, was not without a hint of controversy. In the mid-2000s, their oldest and largest subsidiary, McCann-Erickson, became embroiled in an accounting scandal. Inflated income worth $600 million was uncovered, consequently leaving the company with sanctions from the Securities and Exchange Commission and a lawsuit from its shareholders. These events led the Board of Directors to get a new management team – the same team that brought the company success during trying economic times.

The ups and downs of the Interpublic Group of Companies serve as a model for thriving businesses. They have suffered losses, but they were able to learn from these experiences to bring forth a foolproof business model few companies can match.

Cancer is one of the leading causes of death in the world. Despite the growing number of cases, the cure for this lethal disease has not yet been discovered.

Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by researching and developing treatments for cancer and other severe, immune inflammatory conditions.

This innovative company seeks to deliver life-changing drugs for patients through more than three hundred clinical trials at major medical centers using compounds they produced. These patients may be afflicted with incurable hematological and solid tumor cancers, including multiple myeloma, lung cancer, and prostate cancer. As the manufacturer and distributor of these prescription drugs, Celgene alters the future by giving people another chance at life.

Celgene was initially founded in 1980 as a unit of Celanese Corporation. Six years later, Celgene was spun off as an independent pharmaceutical company. One of the company’s major milestones was the release of THALOMID (thalidomide), a prescription medication  for the acute treatment of erythema nodosum leprosum. They also received approval to market REVLIMID (lenalidomide) for the treatment of patients with transfusion-dependent anemia.

Recently, Celgene pumped forty-five million dollars into Quanticel, a San Francisco-based cancer drug start-up, to discover cancer drugs. With this partnership, Celgene can get an inside track on new cancer drug discoveries made by the smaller company. This is just one of the many initiatives Celgene uses to leverage their efforts in finding a suitable cure for the disease.

Aside from their commitment to clinical accomplishment, Celgene also considers patient support a guiding principle. They believe that people who could benefit from their groundbreaking discoveries should be given such an opportunity. Through industry-leading programs that provide information and access to their innovative therapies, Celgene puts patients at the top of their list of priorities.

As one of the most innovative companies in the field of medicine, Celgene plays an important role in changing the future of the medical industry.